Physician profile
Nancy E Roecklein
NPI 1780922518
$5,357.99
in general payments reported to CMS, 2019-2025
29 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,027 · 2022: $653 · 2023: $674 · 2024: $939 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $581.68 | 2021-2023 | Padcev, Tukysa |
| Janssen Biotech, INC. | $500.22 | 2021-2025 | Carvykti, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $387.79 | 2021-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $324.67 | 2021-2024 | Lynparza |
| Amgen INC. | $293.33 | 2021-2022 | |
| Eisai INC. | $287.54 | 2021-2024 | |
| Abbvie INC. | $286.12 | 2024-2025 | |
| Gilead Sciences, INC. | $276.23 | 2023-2025 | Trodelvy |
| Stemline Therapeutics INC. | $266.47 | 2023-2024 | Orserdu |
| Pfizer INC. | $259.78 | 2021-2025 | |
| Exelixis INC. | $213.79 | 2024-2025 | Cabometyx |
| Novocure INC. | $213.17 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $193.46 | 2021 | |
| Puma Biotechnology, INC. | $173.62 | 2021-2024 | |
| Incyte Corporation | $140.00 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $124.39 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Merck Sharp & Dohme LLC | $92.64 | 2021-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $79.08 | 2021-2024 | |
| Myovant Sciences INC. | $76.04 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.08 | 2021 | |
| Genmab U.S., INC. | $63.06 | 2021-2022 | |
| Clovis Oncology, INC. | $39.36 | 2021 | |
| Celgene Corporation | $29.60 | 2021 | |
| Astellas Pharma US INC | $26.61 | 2024 | Padcev |
| Karyopharm Therapeutics INC. | $19.19 | 2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Roecklein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.